A survey of physician experience and treatment satisfaction using fast-acting insulin aspart in people with type 1 or type 2 diabetes

Figures & data

Table 1. Patient characteristics at faster aspart initiation.

	T1D (n = 177 physicians surveyed)	T2D (n = 166 physicians surveyed)
Baseline treatment regimen MDI of insulin Insulin pumps Newly diagnosed patients Other	122 (69%) 25 (14%) 28 (16%) 3 (2%)
OADs GLP-1 RA (± OAD) Basal (± OAD) Basal plus^‡ Full basal–bolus* Basal + GLP-1 RA (± OAD) Premix (± OAD) CSII/insulin pump Newly diagnosed patients		31 (18%) 15 (9%) 29 (18%) 25 (15%) 35 (21%) 13 (8%) 8 (5%) 5 (3%) 7 (4%)
Switching to faster aspart from other mealtime insulin Initiating faster aspart with no prior mealtime insulin	121 (68%) 56 (32%)	93 (63%)^¶ 56 (37%)^¶
Age (years) ≤30 31–40 41–50 51–65 >65	56 (32%) 44 (25%) 40 (23%) 25 (14%) 12 (7%)	20 (12%) 25 (15%) 46 (28%) 47 (28%) 28 (17%)
BMI (kg/m^2) <25 25–30 31–35 >35	54 (30%) 60 (34%) 42 (24%) 22 (12%)	17 (10%) 44 (27%) 67 (41%) 37 (22%)
HbA1c <7.0% (53 mmol/mol) 7.0–7.5% (53–59 mmol/mol) 7.5–8.0% (59–64 mmol/mol) 8.0–8.5% (64–69 mmol/mol) 8.5–9.0% (69–75 mmol/mol) >9.0% (75 mmol/mol)	16 (9%) 30 (17%) 42 (24%) 41 (23%) 28 (16%) 20 (12%)	13 (8%) 21 (13%) 32 (20%) 42 (25%) 32 (19%) 26 (16%)
Reason for faster aspart initiation	Patients initiating faster aspart (n = 151 physicians surveyed)	Patients switching from another mealtime insulin (n = 183 physicians surveyed)
Concern of inadequately controlled blood glucose (HbA1c)	45 (30%)	50 (27%)
Potential problems of hypoglycemia	23 (15%)	30 (17%)
Concern about postprandial hyperglycemia	24 (16%)	33 (18%)
A need to take corrective mealtime insulin (bolus) doses	21 (14%)	21 (11%)
A need for the option to take their bolus dose after meals	19 (13%)	24 (13%)
A need for the option to take their bolus at mealtime	17 (11%)	24 (13%)
Other	2 (1%)	0 (0%)

T1D other includes: daily insulin, combination, liraglutide, long-acting insulin, OAD, and basal insulin.

*Full basal–bolus, basal + 3 prandial/mealtime insulin (± OAD); ^‡basal plus, basal + 1 or 2 prandial/mealtime insulin (± OAD); ^¶total n = 149.

BMI, body mass index; CSII, continuous subcutaneous insulin infusion; GLP-1 RA, glucagon-like peptide-1 receptor agonist; HbA_1c, glycated hemoglobin; MDI, multiple daily injections; OAD, oral antidiabetic drug; T1D, type 1 diabetes; T2D, type 2 diabetes.

n represents the number of physicians surveyed regarding their T1D or T2D patient caseload.

Table 2. Patients switching to faster aspart from another mealtime insulin.

		Overall	UK	Denmark	Switzerland	Finland	Canada
Switching to faster aspart from another mealtime insulin	T1D	68%	68%	81%	76%	97%	61%
	T2D	63%	66%	92%	63%	86%	56%
Switch patients with change in timing or dose of mealtime insulin, prior to starting faster aspart	T1D	42%	52%	47%	62%	77%	29%
	T2D	37%	50%	20%	31%	62%	31%

T1D, type 1 diabetes; T2D, type 2 diabetes.

Figure 1. Prescription drivers for faster aspart.

Figure 2. Barriers to switching patients to faster aspart. GP, general practitioner.

Figure 3. Physician satisfaction with faster aspart compared with other mealtime insulins.

Data availability statement

The data that support the findings of this study are available from the corresponding author, JDDRF, upon reasonable request.